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First described over 50 years ago, Rett syndrome (RTT) is a neurodevelopmental disorder
caused primarily by mutations of the X-linked MECP2 gene. RTT affects predominantly
females, and has a prevalence of roughly 1 in every 10,000 female births. Prior to the
discovery that mutations ofMECP2 are the leading cause of RTT, there were suggestions
that RTT could be a mitochondrial disease. In fact, several reports documented altered
mitochondrial structure, and deficiencies in mitochondrial enzyme activity in different cells
or tissues derived fromRTT patients. With the identification ofMECP2 as the causal gene,
interest largely shifted toward defining the normal function of MeCP2 in the brain, and
how its absence affects the neurodevelopment and neurophysiology. Recently, though,
interest in studying mitochondrial function in RTT has been reignited, at least in part due
to observations suggesting systemic oxidative stress does play a contributing role in RTT
pathogenesis. Here we review data relating to mitochondrial alterations at the structural
and functional levels in RTT patients and model systems, and present a hypothesis for
how the absence of MeCP2 could lead to altered mitochondrial function and elevated
levels of cellular oxidative stress. Finally, we discuss the prospects for treating RTT using
interventions that target specific aspects of mitochondrial dysfunction and/or oxidative
stress.
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INTRODUCTION
Mutations of the gene encoding methyl-CpG-binding-domain-containing-protein 2 (MECP2) are
the underlying cause for the vast majority of people affected with typical Rett syndrome (RTT;
OMIN #312750) (Amir et al., 1999), with mutations of the genes encoding cyclin-dependent
kinase-like 5 (CDKL5) and forkhead box g1 (FOXG1) also causal for other less common RTT cases
(Weaving et al., 2004; Ariani et al., 2008).MeCP2 is a pleotropic factor, which depending on context,
can repress or stimulate gene expression (Yasui et al., 2007; Chahrour et al., 2008) by regulating both
local and higher-order chromatin organization (Jones et al., 1998; Georgel et al., 2003; Skene et al.,
2010). Through these mechanisms, MeCP2 functions as a key transcriptional control orchestrator
that maintains homeostasis in different cells and systems throughout the body in accordance with
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local demands (Dani et al., 2005; Kron et al., 2012; Li et al.,
2013). Since MeCP2 is globally expressed (Reichwald et al.,
2000; Shahbazian et al., 2002), mutations that negatively affect
MeCP2 function would likely alter transcriptional control in
virtually every cell in the body, albeit to differing levels
depending on the level of MeCP2 expression in any given
cell, and the prevalence of other systems that can partially
compensate for its absence. Given that RTT is a neurological
condition (Johnston et al., 2001; Neul and Zoghbi, 2004), it
is not surprising that the brain expresses the highest levels of
MeCP2 in the body (Shahbazian et al., 2002), and the selective
removal of MeCP2 from neurons is sufficient to induce a RTT-
like phenotype in mice (Chen et al., 2001; Guy et al., 2001).
However, the importance of MeCP2 function in glial cells is
also recognized, as its selective ablation from oligodendrocytes
induces behavioral impairments in mice (Nguyen et al., 2013),
and the reactivation of Mecp2 in only astrocytes of MeCP2-null
mice improves aspects of their RTT-like behavior (Lioy et al.,
2011). Precisely how this pathology arises remains unclear, but
dysregulation of the three-dimensional chromatin organization
and proper coordinated gene expression are likely initiating
points in the pathogenic cascade. As nuclear genes encode the
vast majority of mitochondrial proteins (Gregersen et al., 2012),
the possibility that a MeCP2 deficiency could facilitate alterations
in the expression patterns of mitochondrial factors cannot
be excluded.
Mitochondria are the primary energy producing organelles,
and consequently, defects or changes in mitochondrial gene
expression patterns can affect normal energy production
capacity. Proteins residing within mitochondria are encoded
by both nuclear and mitochondrial genomes (Gregersen et al.,
2012), and it is now established that MeCP2 either directly
or indirectly regulates the expression of several nuclear genes
encoding mitochondrial factors (Kriaucionis et al., 2006; Gibson
et al., 2010; Pecorelli et al., 2013). Given the ubiquitous expression
pattern of MeCP2, any deficit in MeCP2 function could therefore
lead to mitochondrial impairments in any cell type of the body.
However, tissues with elevated energy demands, such as nerve
and muscle, would likely be most susceptible to damage caused
by functionally impaired mitochondria (Wong, 2010). In fact,
the “Mitochondrial Diseases” are a specific category of disorders
that arise from mutations in mitochondrial DNA (mtDNA)- or
nuclear DNA (nDNA)-encoded mitochondrial proteins, which
often disproportionately affect brain function compared to other
organs or systems. Despite being caused by different mutated
genes, many of these diseases share major clinical features.
These include, but are not limited to, early symptomatic onset,
developmental delay, motor and mental regression, dystonia,
ataxia, muscle weakness (hypotonia), cardiomyopathy, seizures,
gastrointestinal reflux, and impaired function of the respiratory
system (Schon and Manfredi, 2003). Mitochondrial diseases are
also characterized by oxidative damage, a decrease in electron
transport chain (ETC) complex activities, and elevated levels
of lactate and pyruvate in blood (Chinnery and Schon, 2003;
Mattman et al., 2011).
Rett syndrome shares many common features with
mitochondrial diseases, although not generally reaching the
same degree of overall severity. In addition to overlaps in
their respective clinical presentations, these similarities include
elevated levels of lactate and pyruvate in blood and cerebrospinal
fluid (Matsuishi et al., 1992; Lappalainen and Riikonen, 1994;
Haas et al., 1995), altered electron transport chain (ETC) complex
function (Kriaucionis et al., 2006; Gold et al., 2014), and evidence
for increased oxidative damage (De Felice et al., 2009, 2011a,b,
2012). Such commonality may not be surprising, as alterations
in the expression patterns of certain nuclear genes that are
themselves causal for specific mitochondrial disorders when
mutated have been observed in RTT patients and model systems
(see below). In fact, clear indices of abnormal mitochondrial
structure and function have been observed in different cell
types derived from both symptomatic MeCP2-deficient mice as
well as RTT patients (Tables 1–3). In MeCP2-deficient mice,
alterations in mitochondrial function are evident at both early
and late stages of symptomatic progression, but differences do
exist in their pattern of dysfunction. For example, while both
pre-symptomatic and symptomatic MeCP2-null mice display
elevated markers for oxidative stress (De Felice et al., 2014), the
burden is higher in mice at symptomatic stages (De Felice et al.,
2014). Similarly, while mitochondrial membrane potential in
hippocampal stratum pyramidale neurons is preserved in brain
slices from pre-symptomatic neonatal MeCP2-null mice (Großer
et al., 2012), it is significantly decreased (depolarized) in the
same cells in symptomatic MeCP2-deficient mice (Großer et al.,
2012). These data not only illustrate that altered mitochondrial
function is one consequence of MeCP2 dysfunction, but also
suggest that there is progressivity in dysfunction as symptomatic
severity increases. Further, they raise the possibility that impaired
mitochondrial function could indeed play a contributing rather
than passive role in RTT pathogenic progression. Finally, the
decreased ATP levels that have been observed in the symptomatic
MeCP2-null mouse brain (Saywell et al., 2006), in the female
Mecp2308 mouse brain (De Filippis et al., 2015), and in isolated
Mecp2−/y microglia (Jin et al., 2015) provides further evidence
that the absence of MeCP2 leads to impaired mitochondrial
function.
EVIDENCE FOR INCREASED OXIDATIVE
STRESS IN RETT SYNDROME TISSUES
AND MODEL SYSTEMS
Since mitochondria are the major sites of reactive oxygen species
(ROS) production and also contribute to ROS detoxification,
mitochondrial dysfunction generally results in excessive ROS
production and/or diminished ROS detoxification, which
collectively heighten levels of oxidative stress. As mentioned
previously, elevated oxidative stress has repeatedly been reported
in RTT patients. In Sierra et al. (2001) showed a decrease
in the activity of superoxide dismutase in erythrocytes from
RTT patients, and an increase in plasma malondialdehyde, a
marker of lipid peroxidation. Later, De Felice et al. (2009)
also demonstrated the presence of oxidative stress markers
such as intra erythrocyte and plasma non-protein-bound iron
(NPBI; i.e., free iron), esterified F2-isoprostanes (F2-IsoPs, as
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TABLE 1 | Genes encoding oxidative phosphorylation factors that display altered expression in MeCP2-deficient systems.
Gene Coding
genome
Protein function 1 Cell/tissue type Organism References
Mt-Nd2 mtDNA NADH-dehydrogenase subunit 2
(complex I)
↓ Brain tissue MeCP2-null mice Kriaucionis et al., 2006
NDUFA 1, 2, 8, 9
NDUFB 2, 4, 6, 9, 10
NDUFC 1, 2
NDUFS 4, 5, 6
NDUFV 2
nDNA NADH: ubiquinone
oxidoreductase (complex I)
↑ Lympho-monocytes Human (RTT patients) Pecorelli et al., 2013
SDHB nDNA Succinate dehydrogenase
complex, subunit B (complex II)
↑ Lympho-monocytes Human (RTT patients) Pecorelli et al., 2013
Uqcrc1 nDNA Cytochrome b-c1 complex
subunit1 (complex III)
↑ Brain tissue MeCP2-null mice Kriaucionis et al., 2006
UQCRC1 nDNA Cytochrome b-c1 complex
subunit1 (complex III)
↓ ESC derived MeCP2-null
neurons
Human Li et al., 2013
UQCRQ UQCRFS1
UQCRH
nDNA Subunits of complex III ↑ Lympho-monocytes Human (RTT patients) Pecorelli et al., 2013
CO1 mtDNA Cytochrome c oxidase subunit 1
(complex IV)
↓ Frontal and occipital cortex Human (RTT patients) Gibson et al., 2010
MeCP2-null SH-SY5Y Human Gibson et al., 2010
Skeletal muscles MeCP2-null mice Gold et al., 2014
COX14, COX6C,
COX7C, 7A2, 8A
nDNA Subunits of cytochrome c
oxidase (complex IV)
↑ Lympho-monocytes Human (RTT patients) Pecorelli et al., 2013
ATP5A1,
ATP5EP2,
ATP5J2,
ATP5O
nDNA Subunits of ATP synthase
(complex V)
↑ Lympho-monocytes Human (RTT patients) Pecorelli et al., 2013
ATPIF1 nDNA ATPase inhibitory factor 1 ↑ Lympho-monocytes Human (RTT patients) Pecorelli et al., 2013
ANT1 nDNA Adenine nucleotide transporter ↑ Brain tissue, cerebellum, skeletal
muscles
MeCP2-null mice Forlani et al., 2010
CYCS nDNA Electron carrier cytochrome c ↑ Lympho-monocytes Human (RTT patients) Pecorelli et al., 2013
TABLE 2 | Genes displaying altered expression in MeCP2-deficient systems that encode mitochondrial structural and organization factors.
Gene Coding genome Protein function 1 Cell/ tissue type Organism References
HMN mtDNA 16sRNA ↑ Brain tissue Human (RTT patients) Gibson et al., 2010
TIMM 8B, 9, 10, 13, 17A
TOMM7 TSPO
nDNA Mitochondrial import and
localization
↑ Lympho-monocytes Human (RTT patients) Pecorelli et al., 2013
MRPL13, 20, 21, 33, 51, 52
MRPS25, 30, 33, 36
nDNA Mitochondrial ribosomal
proteins
↑ Lympho-monocytes Human (RTT patients) Pecorelli et al., 2013
ESC-derived neurons1 Human (RTT patients) Tanaka et al., 2013
Pgc-1α nDNA Mitochondrial biogenesis ↓ Skeletal muscles MeCP2-null mice Gold et al., 2014
Crls1 nDNA Synthesis of cardiolipin ↓ Skeletal muscles MeCP2-null mice Gold et al., 2014
NR3C1 nDNA Mitochondrial transcription
factor
↑ ESC-derived neurons Human (RTT patients) Tanaka et al., 2013
TABLE 3 | Genes displaying altered expression in MeCP2-deficient systems that encode oxidative defense factors.
Gene Coding genome Protein function 1 Cell/ tissue type Organism References
SOD1 nDNA ROS scavenging enzyme ↑ Hippocampus MeCP2-null mice Großer et al., 2012
Lympho-monocytes Human (RTT patients) Pecorelli et al., 2013
CAT nDNA Catalase ↑ Lympho-monocytes Human (RTT patients) Pecorelli et al., 2013
PRDX1 nDNA Peroxiredoxin ↑
GSTO1 nDNA Glutathione S-transferase omega 1 ↑
MGST2,
MGST3
nDNA Microsomal glutathione S-transferase ↑
Prdh nDNA Proline dehydrogenase ↑ Brain tissue MeCP2-null mice Urdinguio et al., 2008
Ucp3 nDNA Uncoupling protein 3 ↓ Skeletal muscles MeCP2-null mice Gold et al., 2014
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free, esterified, and total forms), and protein carbonyls in
RTT patients indicative of both systemic oxidative stress and
lipid peroxidation. In subsequent studies they also reported the
presence of oxidative stress markers in different RTT patient
group blood samples (De Felice et al., 2011a, 2012; Leoncini
et al., 2011), and elevated levels of oxidative stress markers such
as intra erythrocyte and plasma NPBI, plasma F2-IsoPs and
4-hydroxynonenal protein adducts (4-HNE PAs) in additional
RTT patients (Ciccoli et al., 2012). More recently Signorini
et al. (2014) reported significant increases in F4-Neuroprostanes
(F4-NeuroPs), F2-IsoPs, NPBI, and 4-HNE PAs, together with
a significant decrease in reduced glutathione (GSH)—one of
the major non-enzymatic endogenous antioxidants—in skin
fibroblasts from RTT patients. These observations not only
illustrate evidence for elevated oxidative damage in RTT
patients, but also implicate decreased anti-oxidative defense as a
mitigating mechanism.
Similar heightened levels of oxidative stress have also been
observed in MeCP2-null mouse models. Elevated mitochondrial
respiration rates and a reduction in coupling were detected
in MeCP2-null male mouse brains (Kriaucionis et al., 2006).
Hippocampal slices from MeCP2-null male mice displayed
higher oxidized baseline conditions, increased oxidative burden
and reduced activity of the ROS scavenger SOD1 (Großer et al.,
2012). Oxidative stress markers (F4-NeuroPs, F2-IsoPs, NPBI,
and 4-HNE PAs) were significantly elevated in brain samples of
MeCP2-null (pre-symptomatic and symptomatic) and Mecp2308
mutated (pre-symptomatic and symptomatic) male and female
mice (De Felice et al., 2014). Interestingly, after reactivation of
MeCP2 in the brain of previously MeCP2-null mice, the levels
of the oxidative stress markers F4-NeuroPs, F2-IsoPs, and NPBI
were restored to wild type levels (De Felice et al., 2014). These
results illustrate the increased oxidative burden stems directly
from the absence of MeCP2, and importantly, that it is not
permanent and can be abrogated. Finally, and consistent with
RTT patient data, a decrease in the GSH/GSSG ratio has been
observed in the brains of MeCP2-null mice (Szczesna et al.,
2014), along with a decrease in GSH levels in skeletal muscles of
symptomatic MeCP2-null mice (Gold et al., 2014). Collectively,
these data provide further indication that the absence of MeCP2
is causal for a significant increase in oxidative stress indicators in
the brain of mice.
MITOCHONDRIAL STRUCTURE IS
ALTERED IN RETT SYNDROME PATIENTS
AND MODEL SYSTEMS
Several studies of mitochondria in different tissues of RTT
patients and MeCP2-null mouse models have also identified
alterations in mitochondrial ultrastructure. Electron microscopic
analyses of muscle and skin biopsies revealed the presence
of abnormally swollen and dumb-bell shaped mitochondria
with vacuolization, abnormally elongated mitochondria with
vacuolization and concentric membranous profiles, and
oversized mitochondria that had fewer and shorter cristae
than normal (Eeg-Olofsson et al., 1988, 1990; Ruch et al.,
1989; Wakai et al., 1990; Dotti et al., 1993; Cornford et al.,
1994; Cardaioli et al., 1999). Similar swollen and vacuolated
mitochondria have also been seen in sural nerve biopsies from
RTT patients (Wakai et al., 1990), and in neurons from the
frontal cortex, cerebellum and substantia nigra in postmortem
patient samples (Cornford et al., 1994). Analysis of mitochondria
from MeCP2-null mice revealed commonalities with the
findings in RTT patients. Ultrastructural analysis of neurons
within brain slices from 3 week old male Mecp2tm1.1Bird and
Mecp2tm1.1Jaenisch strains of mice found enlarged, elongated
mitochondria with enlarged cristae in hippocampal neurons
(Belichenko et al., 2009). Similarly, studies of muscles from
8-week old male Mecp2tm1.1Jaenisch mice reported enlarged
and misshapen mitochondria with electron-lucent central
matrices and non-parallel, disorganized, cristae (Park et al.,
2014). These observations are not absolute, however, as despite
observing significant alterations in mitochondrial function in
brain samples taken from 12 week old male Mecp2tm1.1Bird,
Kriaucionis et al. (2006) reported the absence of gross structural
abnormalities in mitochondria purified total brain relative
to age-matched wild-type mice. Thus, while morphological
alterations are commonly observed, mitochondria with
seemingly normal morphologies can still display pronounced
functional deficiencies in MeCP2-deficient tissues. These data
suggest that the observed morphological changes are late
occurring events in RTT symptomatic progression, and may be a
consequence of chronically elevated mitochondrial stress.
THE EXPRESSION LEVELS OF GENES AND
PROTEINS RELATED TO MITOCHONDRIAL
FUNCTION ARE ALTERED IN
MECP2-DEFICIENT CELLS
Nuclear genes encode more than 99% of mitochondrial
proteome, with the remaining proteins encoded by the
mitochondrial genome (Gregersen et al., 2012). Several studies
have reported alterations in the expression profiles of different
mitochondrial factor-encoding genes in samples from RTT
patients, MeCP2-null mouse models, and MeCP2-deficient
cell lines. Although the specific factors identified in each
individual study were largely non-overlapping, the collective
results suggest the normal homeostasis of mitochondria in
MeCP2-deficient cells is indeed altered by the absence of MeCP2.
Common themes emerging from these studies were: (1) the
upregulated expression of several nuclear-encoded components
of ETC Complexes I, II, III, and IV (Kriaucionis et al., 2006;
Gibson et al., 2010; Pecorelli et al., 2013); (2) an induction
in the expression of genes encoding proteins that regulate
mitochondrial structure/organization (Pecorelli et al., 2013); (3)
the upregulation of different mitochondrial ribosomal factors
involved with translation (Pecorelli et al., 2013); (4) an induction
of factors directly involved with maintaining mitochondrial
functional homeostasis (Forlani et al., 2010; Tanaka et al., 2013);
and (5) an induction of factors involved with anti-oxidative
defense (Großer et al., 2012; Pecorelli et al., 2013). In addition
to upregulated expression changes, there were also notable
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mitochondrial factors that showed diminished expression in
MeCP2-deficient systems. These include cytochrome c oxidase
(complex IV) (Gibson et al., 2010; Gold et al., 2014), the
transcriptional regulator PGC-1α, mitochondrial uncoupling
protein 3, cardiolipin synthase (Gold et al., 2014), and NADH-
dehydrogenase subunit 2 (Kriaucionis et al., 2006). The pattern
of change for NADH-dehydrogenase subunit 2 was particularly
intriguing, as while decreases were evident inMeCP2-null mice at
full symptomatic stages, no changes in expression were observed
at pre- or early symptomatic stages of development. This result
further supports the hypothesis that mitochondrial expression or
functional changes are progressive over time in MeCP2-deficient
systems.
EVIDENCE FOR ALTERED
MITOCHONDRIAL FUNCTION IN
MECP2-DEFICIENT CELLS
The differential expression of genes coding for subunits of the
ETC complexes in RTT patients and MeCP2-deficient mouse
models strongly suggest that the function of these complexes
will be correspondingly altered in MeCP2-deficient systems. One
likely alteration would be mitochondrial membrane potential.
Mitochondrial membrane potential is created when protons are
pumped from the mitochondrial matrix into the inter-membrane
space as electrons pass through the ETC (Mitchell, 1961; Jastroch
et al., 2010). An increased mitochondrial membrane potential
is indicative of an increased rate of electron transport through
the ETC, while a decreased potential is indicative of decreased
ETC transport and could also be indicative of increased proton
leak. In different cells from MeCP2-deficient mice, decreased
mitochondrial membrane potential has been observed (Großer
et al., 2012; Janc and Müller, 2014), suggestive of decreased
ETC activity and/or increased proton leak. Functional studies
have supported this, as Gibson et al. (2010) showed decreased
cytochrome c oxidase activity (Complex IV) in SH-SY5Y cells
following MeCP2 knockdown, and Gold et al. (2014) reported
a marked decrease in the activities of Complexes II, Complex
III and Complex IV in both cerebellum and skeletal muscle
of symptomatic MeCP2-null mice. Additional studies have
reported increased respiration rates—but lower mitochondrial
efficiencies—in mitochondria isolated from acute MeCP2-null
mouse hippocampal slices (Großer et al., 2012), along with
decreased ATP levels in both MeCP2-null mice brains (Saywell
et al., 2006), and in MeCP2-null microglia cells (Jin et al., 2015).
Similarly, Kriaucionis et al. (2006) reported that symptomatic
MeCP2-null mice display increased expression of ubiquinol-
cytochrome c reductase core protein 1 (Uqcrc1), and increased
uncouple respiration rates upstream of complex IV. From data
obtained by Uqcrc1 over-expression in N2A cells, they speculated
that such Uqcrc1 upregulation could exacerbate normal electron
transfer rates in the complex III assembly, and underlie the
increased uncoupled respiration rates they observed in the
MeCP2-null brain samples (Kriaucionis et al., 2006). Taken
together, these studies provide strong evidence that MeCP2
deficiency does compromise the ability of mitochondrial to carry
out oxidative phosphorylation.
HOW MIGHT MECP2 DYSFUNCTION LEAD
TO IMPAIRED MITOCHONDRIAL
FUNCTION?
The studies discussed above indicate clearly that the absence
of MeCP2 affects mitochondrial function. Precisely how this
arises remains unclear, but the available evidence does suggest a
progressive cascade (Müller and Can, 2014). In MeCP2-deficient
cells there appears to be an early dysregulation of the normal
expression patterns for key nuclear and mitochondrial DNA-
encoded factors that are essential for proper mitochondrial
function. These changes (and likely others of currently unknown
etiology) initially lead to mitochondrial hyperpolarization
(Galloway and Yoon, 2012), which could be viewed as a
compensatory attempt to increase ATP production in a system
with diminished ATP synthesis efficiency and/or increased
ATP demands. However, this hyperpolarization, in conjunction
with impairments in specific ETC complexes, facilitates an
overproduction of ROS that over time reinforces a vicious cycle
of that eventually compromises mitochondrial function, and
causes mitochondrial depolarization (Großer et al., 2012; Janc
and Müller, 2014). When this state is reached, the ability of
mitochondria to produce ATP is further diminished, and the
capacity of ATP-dependent cellular mechanisms is compromised.
The swelling of MeCP2-deficient mitochondria observed in
different systems could reflect a byproduct to the increased
demand on the system to provide sufficient ATP to maintain
cellular homeostasis.
A MODEL FOR HOW ANT1
DYSREGULATION COULD PLAY A ROLE IN
MITOCHONDRIAL DYSFUNCTION
While the precise mechanisms that initiate this feed-forward
process remain speculative, and could involve multiple entry
points, there are intriguing data to suggest the adenine nucleotide
transporter (ANT1) may be a potential mediator. ANT1 is a
transmembrane protein responsible for the normal shuttling
of ATP and ADP across the inner mitochondrial membrane
(Forlani et al., 2010). Under normal conditions, MeCP2 binds
to methyl CpG sites in the promoter region of the ANT1 gene,
and together with the zinc finger epigenetic regulator yin-yang
1 (YY1), negatively regulates ANT1 expression. In the absence
of MeCP2, ANT1 would become de-repressed, leading to an
elevation in its expression. In fact, in MeCP2-null mouse brain,
fibroblasts derived from RTT patients, and several MeCP2-
null cell lines show a significant increase in ANT1 expression
(Forlani et al., 2010). This is intriguing, as ANT1 represents a
site at which proton leak back across the inner mitochondrial
membrane can occur. In fact, up to two-thirds of the normal basal
proton leak observed in normally functioning mitochondria
occurs through ANT1 (Brand et al., 2005). Importantly, this
leak is directly dependent upon ANT1 prevalence, and is not
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dependent of ANT1 catalytic activity (Jastroch et al., 2010). Since
the magnitude of the proton leak correlates specifically with the
abundance of ANT1 (Jastroch et al., 2010), the increase of ANT1
in MeCP2-null cells could represent an initiation site for an
enhanced basal proton leak. Any such increase in proton leak
via ANT1 would likely initiate a compensatory increase in ETC
activity to maintain ATP production, as reported by Kriaucionis
et al. (2006). However, such an increase in ETC activity would
also lead to an increase the number of electrons liberated from
Complexes I and III, and thus contribute to increased cellular
ROS levels (Mailloux and Harper, 2012). The net result would
be mitochondria with increased proton leak, accelerated electron
transfer rates, increased electron leak, and decreased respiratory
control ratios (Kriaucionis et al., 2006). Initially, mitochondria
compensate to preserve functional efficiency, but over time, the
cumulative effects overcome compensatory function and the
mitochondria depolarize and swell. Such a cycle would predict
that the MeCP2-deficient system has an intrinsically limited
ability to respond to energy demands (e.g., the presence of higher
than normal ADP levels), which restricts its capacity to properly
increase ATP synthesis in specific times of need (Brand and
Nicholls, 2011).
TARGETING MITOCHONDRIAL
DYSFUNCTION IN MECP2-NULL
NEURONS
It is important to note that many RTT patients live into their
5th or 6th decade, and MECP2 mutations are not generally
associated with neurodegeneration (Tarquinio et al., 2015).
These observations argue that MeCP2-deficient cells can meet
most of their essential needs, but are unable to function
within a normal homeostatic window, and display a “failure
to thrive” phenotype rather than one progressing toward a
degenerative endpoint. This therefore indicates that the degree
of mitochondrial impairment in MeCP2-deficient cells is not as
robust as seen in many mitochondrial diseases, which may well
afford a greater chance for therapeutic success. In fact, the pattern
of differential expression of both mitochondrial and nuclear
genes encoding ETC complex components, and other salient
mitochondrial factors inMeCP2-deficient systems, are consistent
with the idea that stressed mitochondria are attempting to
improve their functional efficiency to meet homeostatic needs.
The fact that mitochondrial impairments are not pronounced
in pre-symptomatic or early symptomatic MeCP2-deficient
mice, but rather develop more concomitantly with symptomatic
manifestations, suggest the observed mitochondrial impairments
may be linked to overall disease progression. The model
presented here is one of a “feed-forward” cycle that becomes
active over time as oxidative stress levels accumulate. That
is, loss of MeCP2 function causes deregulation of nuclear
genes encoding key proteins required to maintain mitochondrial
function within a normal range, and as a consequence, the
mitochondria work harder but with diminished efficiency to
meet energy demands. Over time, the elevated electron leak
progressively increases cellular oxidative stress, which further
impairs the functional capacity of mitochondria. Thus, therapies
that globally target various aspects of mitochondrial function or
mitochondrial ROS production and biogenesis could potentially
delay symptomatic onset and/or severity if administered at early
pre-symptomatic stages, and/or interrupt the cycle and improve
existing symptoms if administered at later stages.
There are data that support this possibility. For example, the
administration of Trolox, a vitamin E derivative, to MeCP2-
null hippocampal slices decreased levels of oxidative burden,
and improved both short- and long-term synaptic potentiation
deficits of the local circuitry (Großer et al., 2012; Janc and
Müller, 2014). In addition, Janc et al. (2016) recently reported
that while the administration of Trolox to MeCP2-null mice did
not improve their ambulatory or respiratory phenotypes, it did
significantly reduce their levels of oxidative stress and improve
their blood glucose levels, short-term synaptic plasticity, and
exploratory behavior phenotypes. Further, the administration
of ω-polyunsaturated fatty acids (ω-PUFAs), which provide
anti-oxidative protection, significantly decreased the levels of
oxidative stress markers in the blood of RTT patients, and
reduced the severity of motor-related impairments, non-verbal
communication deficits, and breathing abnormalities in the same
patients (De Felice et al., 2012). The findings that interventions
targeting excessive ROS in MeCP2-deficient systems and in
RTT patients have provided tangible benefits supports the
hypothesis that mitochondrial impairments linked to oxidative
stress directly contribute to RTT pathogenesis, and are not simply
secondary consequences that appear after full symptomatic
progression has occurred (Müller and Can, 2014). These data
therefore support exploring additional prospective therapies in
RTT models, and potentially RTT patients, that are designed
to attenuate oxidative stress, and/or improve the functional
efficiency of mitochondria.
SUMMARY
Considerable data show impaired mitochondrial function occurs
in MeCP2-deficient cells, and mechanisms through which these
functional alterations arise beginning to be identified. Studies
to date indicate that the loss of MeCP2 function negatively
affects the signaling efficiency of a host of intracellular signaling
pathways, the communicative ability of neuronal populations,
the excitability of neural networks, and the functional efficiency
of mitochondria. Each of these alterations could conceivably
represent targets for therapeutic development toward treating
RTT. The fact that anti-oxidant strategies has improved local
neural circuit activity in vitro and perhaps in vivo in RTT
patients suggests mitochondrial regulation represents a target
that allows at least some functional rescue to be attained.
Intriguingly, a role for Foxg1 in mitochondrial function has
now been identified (Pancrazi et al., 2015), and heightened
levels of oxidative stress markers have been reported in RTT
patients with CDKL5 mutations (Pecorelli et al., 2011). While
it remains unclear if there is mechanistic commonality between
mitochondrial deficiencies in these conditions and those arising
from MeCP2 absence, these data do suggest that impaired
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mitochondrial function may also play a role in atypical RTT
cases. While additional work is needed to resolve the magnitude
to which impaired mitochondrial function contributes to RTT
pathogenesis, the recent data reviewed here strongly suggest
a re-visitation of the “mitochondrial hypothesis of RTT,”
and the prospects for interventions targeting mitochondria, is
warranted.
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